![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Futility Rules in Telaprevir Combination Treatment
|
|
|
Reported by Jules Levin
HEP DART 2011, Koloa, Hawaii, USA, December 4-8, 2011
N Adda1*, L Gritz1, TL Kieffer1, DJ Bartels1, S De Meyer2, F Tomaka3, L Bengtsson1, D Luo3, IM Jacobson4, RS Kauffman1, and G Picchio3
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2Tibotec BVBA, Beerse, Belgium; 3Tibotec Inc., Titusville, New Jersey, United States; 4Weill Cornell Medical College, New York, NY, United States
![HepDart1.gif](../images/120611/120611-2/HepDart1.gif)
![HepDart2.gif](../images/120611/120611-2/HepDart2.gif)
![HepDart3.gif](../images/120611/120611-2/HepDart3.gif)
![HepDart4.gif](../images/120611/120611-2/HepDart4.gif)
![HepDart5.gif](../images/120611/120611-2/HepDart5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|